Q-omics provides the consensus-scored PHYHD1 profile across patient tissues and cancer cell-line models. PHYHD1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PHYHD1 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, PHYHD1 protein abundance shows 24,073 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KIRC, and LSCC as cancer lineages where PHYHD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHYHD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHYHD1 survival associations across molecular data types. PHYHD1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHYHD1 RNA expression–survival associations across cancer types. High PHYHD1 expression shows favorable associations in KIRP, UVM, MESO, UCEC, BRCA and ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PHYHD1 RNA expression.
This table summarizes PHYHD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PHYHD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHYHD1 shows lower tumor expression in KIRC, HNSC, BLCA, KICH, COAD and KIRP. The KIRC box plot shows higher PHYHD1 RNA expression in normal versus tumor tissue (log2 FC = −3.551, t-test p < 0.001).
This table shows molecular features associated with PHYHD1 in patient tissues and cancer cell lines. In patient samples, PHYHD1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PHYHD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
